Community pharmacy, disease state management, and adherence to medication: A review

Disease Management and Health Outcomes

Volumn 16, Issue 4, 2008, Pages 245-254

  Armour, Carol Lyn ^a   Smith, Lorraine ^a   Krass, Ines ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Disease management programmes; Patient compliance; Pharmaceutical services

Indexed keywords

ASTHMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMMUNITY CARE; DIABETES MELLITUS; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; REVIEW; SELF REPORT; TREATMENT OUTCOME;

EID: 49549121096     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200816040-00005     Document Type: Review

References (37)

1. Benrimoj CSI, Frommer MS. Community pharmacy in Australia. Aust Health Rev 2004; 28: 238-46
2. Royal Pharmaceutical Society of Great Britain. Patient counselling audit. 2006 [online]. Available from URL: http://www.rpsgb.org/pdfs/pat_coun.pdf [Accessed 2007 Apr 11]
3. Chen TF, Crampton M, Krass I, et al. Collaboration between community pharmacists and GPs in innovative clinical services: a conceptual model. J Soc Admin Pharm 1999; 16: 134-44
4. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-43
5. Scott IA, Denaro CP, Bennett CJ, et al. Achieving better in-hospital and after-hospital care of patients with acute cardiac disease. Med J Aust 2004; 180 (10 Suppl.): S83-8
6. Sabate E, editor. Adherence to long term therapies: evidence for action. Geneva: World Health Organisation, 2003 [online]. Available from URL: http://www.who.int/chp/knowledge/publications/adherencerep.pdf [Accessed 2008 Apr 15]
7. Horne R. Implications for asthma treatment compliance, adherence and concordance. Chest 2006; 130: 65-72
8. Kripalani S, Yao X, Haynes B. Interventions to enhance medication adherence in chronic conditions. Arch Intern Med 2007; 167: 540-9
9. Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of pharmacist intervention for asthma control improvement. Eur Respir J 2008; 31: 790-9
10. Holland R, Brooksby I, Lenaghan E, et al. Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomized controlled trial. BMJ 2007; 334: 1098. Epub 2007 Apr 23
11. Mangiapane S, Schulz M, Mühlig S, et al. Community pharmacy-based pharmaceutical care for asthma patients. Ann Pharmacother 2005; 39: 1817-22
12. Armour C, Bosnic-Anticevich S, Brillant M, et al. Pharmacy asthma care program (PAC) improves outcomes for patients in the community. Thorax 2007; 62: 496-502
13. Cordina M, McElnay JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy 2001; 21: 1196-203
14. Smith L, Bosnic-Anticevich SZ, Mitchell B, et al. Treating asthma with a self-management model of illness behaviour in an Australian community pharmacy setting. Soc Sci Med 2007; 64: 1501-11
15. Weinberger M, Murray MD, Marrero DG, et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA 2002; 288: 1594-602
16. Armour C, Taylor S, Hourihan F, et al. Implementation and evaluation of Australian pharmacists' diabetes care services. J Am Pharm Assoc 2004; 44: 455-66
17. Krass I, Armour CL, Mitchell B, et al. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med 2007; 24: 677-83
18. Blenkinsopp A, Phelan M, Bourne J, et al. Extended adherence support by community pharmacists for patients with hypertension: a randomised controlled trial. Int J Pharm Pract 2000; 8: 165-75
19. Gordois A, Armour C, Brillant M, et al. Cost-effectiveness analysis of a pharmacy asthma care program in Australia. Dis Manage Health Outcomes 2007; 15: 1-15
20. Taylor SJ, Milanova T, Hourihan F, et al. Cost-effectiveness analysis of a community pharmacist initiated disease state management service for type 2 diabetes mellitus. Int J Pharm Pract 2005; 13: 33-40
21. Krass I, Armour CL, Mitchell B, et al. The Pharmacy Diabetes Care Program: final report to The Commonwealth Department of Health and Ageing as part of the Third Community Pharmacy Research and Development Grants Program. 2005 Apr [online]. Available from URL: http://www.guild.org.au/uploadedfiles/ Research_and_Development_Grants_Program/Projects/2002-518_fr.pdf [Accessed 2007 Aug 30]
22. Saini B, Filipovska J, Bosnic-Anticevich S, et al. An evaluation of a community pharmacy-based rural asthma management service. Aust J Rural Health 2008: 16: 100-8
23. Saini B, Krass I, Armour C. Development, implementation, and evaluation of a community pharmacy-based asthma care model. Ann Pharmacother 2004; 38: 1954-60
24. Blumi M, McKenney J, Cziraky M. Pharmaceutical care services and results in project ImPACT: hyperlipidaemia. J Am Pharm Assoc 2000; 40: 157-65
25. Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma education in the community pharmacy setting: a pilot study. J Asthma 2007; 44: 57-64
26. Svarstad BL, Chewning BA, Sleath BL, et al. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Counsel 1999; 37: 113-24
27. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002; 17: 17-32
28. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self reported measure of medication adherence. Med Care 1986; 24: 67-74
29. Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003; 43: 149-59
30. Wermeille J, Bennie M, Brown I, et al. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team. A pilot study. Pharm World Sci 2004; 26: 18-25
31. Berringer R, Shibley MC, Cary CC, et al. Outcomes of a community pharmacy-based diabetes monitoring program [comment]. J Am Pharm Assoc 1999; 39: 791-7
32. MacDonough RP, Doucette WR. Drug therapy management: an empirical report of drug therapy problems, pharmacists interventions, and results of pharmacists actions. J Am Pharm Assoc 2003; 43: 511-8
33. Bouvy ML, Heerdink ER, Urquhart J, et al. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail 2003; 9: 404-11
34. Tsuyuki RT, Olson LO, Dubyk AM, et al. Effect of community pharmacist intervention on cholesterol levels in cardiovascular patients of high risk of cardiovascular events: the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Am J Med 2004; 116: 130-3
35. Chabot I, Moisan J, Gregoire JP, et al. Pharmacist intervention program for control of hypertension. Ann Pharmacother 2003; 37: 1186-93
36. Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005; 39: 508-15
37. Van Wijk BLG, Klungel OH, Heerdink ER, et al. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother 2005; 39: 319-28